Most Clicked StoriesMore >


Biogen moves closer to spinning off hemophilia business

BIO SmartBrief | Jan 17, 2017

Bioverativ will be spun off from Biogen, and the management team of the hemophilia enterprise plans to pursue partnerships. The spinoff is not intended to draw bids from potential buyers, said John Cox, who will lead the new company. FiercePharma (01/11)


FDA finalizes guidance on naming of biologics and biosimilars

BIO SmartBrief | Jan 13, 2017

Takeda, Maverick sign $125M cancer therapy collaboration

BIO SmartBrief | Jan 13, 2017

Merck KGaA gains 4 Vertex cancer programs

BIO SmartBrief | Jan 16, 2017

Forward Pharma gains $1.25B from Biogen for patent settlement agreement

BIO SmartBrief | Jan 18, 2017

Sanofi gains license to ImmuNext's autoimmune disease therapy

BIO SmartBrief | Jan 17, 2017

FDA grants orphan status to Sangamo's lysosomal storage disease treatment

BIO SmartBrief | Jan 12, 2017

Moderna announces R&D lineup

BIO SmartBrief | Jan 12, 2017

Merck expands immuno-oncology partnership with Eli Lilly

BIO SmartBrief | Jan 12, 2017

FDA fast-tracks ViraCyte's T-cell immunotherapy

BIO SmartBrief | Jan 12, 2017


Find BIO SmartBrief Issues by Date:



BIO News More >


Nikon

BIO SmartBrief | Jan 18, 2017

Register for the 2017 BIO CEO & Investor Conference in NYC

BIO SmartBrief | Jan 18, 2017

Unifirst

BIO SmartBrief | Jan 17, 2017

Are you looking for top biotech talent? Or looking for a biotech job?

BIO SmartBrief | Jan 17, 2017

Office Depot -- Latest

BIO SmartBrief | Jan 16, 2017




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more